reference/31860455

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31860455

Outgoing Links

Predicate	Object
contentType	Journal Article\|Multicenter Study\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	813
issn	1527-3792 0022-5347
issueIdentifier	4
pageRange	805-813
publicationName	The Journal of urology
startingPage	805
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_15efc6190f3be0fb3582a4f2b162ac6c http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_439eaa3a060cee9558b72b5b44408fde http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_00e62befd511305fa8782153ecceb5c9
bibliographicCitation	Waisman Malaret AJ, Chang P, Zhu K, Zheng Y, Newcomb LF, Liu M, McKenney JK, Brooks JD, Carroll P, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Lin DW, Wagner AA. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Journal of Urology. 2022 Apr;207(4):805–13. doi: 10.1097/ju.0000000000002354.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89853b7f15dd47ed76c5ad4a9599d7e6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_63c4a820ba5945dcd85d631dad41c53e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40df825619529e19b4f08715ae8fe517 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_926b5899d144c0bae6bb0309f934e3b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-4175-8638 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d08bf03834d16555394b5f04e90c569f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_79e07034484781dc8b6e93465ce794e5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89ff091d23225ee74058b29ae7e982ee http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db6a5215ed97dc1c9a78bd201c91389c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76f4b4c1af032775aaa1a1d2542aa2b2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5d772ae9ea9562d5be9c70561806384 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60970449f1c62beea7b56f7f42339831 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e936e535dadeca235d09a9364e2aa1c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b59ca39fbdfbdbe4ae87084aa11447a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3bc08875e940716e9c71b881f0dfe3e8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cb7d57ddbd3fc2a38362d32d1a9227b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8503e1fbf599dd58d01d42e396fa2f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3891dbbf9e66e0fcd347302a7aadbe11
date	202204
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC8917057 https://doi.org/10.1097/ju.0000000000002354 https://pubmed.ncbi.nlm.nih.gov/34854745
isPartOf	https://portal.issn.org/resource/ISSN/1527-3792 https://portal.issn.org/resource/ISSN/0022-5347 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5331
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D011471Q000473 http://id.nlm.nih.gov/mesh/D011468 http://id.nlm.nih.gov/mesh/D057832 http://id.nlm.nih.gov/mesh/D011471Q000601
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D009364 http://id.nlm.nih.gov/mesh/D011446 http://id.nlm.nih.gov/mesh/D001706 http://id.nlm.nih.gov/mesh/D060787 http://id.nlm.nih.gov/mesh/D014481 http://id.nlm.nih.gov/mesh/D018570 http://id.nlm.nih.gov/mesh/D002170 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D012044 http://id.nlm.nih.gov/mesh/D061665 http://id.nlm.nih.gov/mesh/D011471Q000145 http://id.nlm.nih.gov/mesh/D016016
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_06fc07ae833868882f2751f12834b78e http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983

Total number of triples: 63.